Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.48 |
| ▸ | CDK2 | P24941 | 11/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413081 | 1.00 | CDK4 (0.48) | CDK4CDK2EIF2AK2JAK2FLT3 | |
| SCHEMBL14011298 | 0.89 | EIF2AK2 (0.48) | CDK4CDK2EIF2AK2JAK2FLT3 | |
| SCHEMBL4425029 | 0.89 | EIF2AK2 (0.46) | CDK4CDK2EIF2AK2JAK2FLT3 | |
| SCHEMBL4425032 | 0.89 | EIF2AK2 (0.46) | CDK4CDK2EIF2AK2JAK2FLT3 | |
| SCHEMBL8317782 | 0.87 | EIF2AK2 (0.45) | CDK4CDK2EIF2AK2JAK2FLT3 | |
| SCHEMBL4420428 | 0.85 | CDK4 (0.53) | CDK4CDK2EIF2AK2 | |
| SCHEMBL14011247 | 0.79 | MAPK1 (0.43) | CDK4CDK2EIF2AK2MAPK1 | |
| SCHEMBL4424686 | 0.76 | CDK4 (0.48) | CDK4CDK2EIF2AK2 | |
| SCHEMBL8316804 | 0.70 | CDK4 (0.59) | CDK4CDK2EIF2AK2JAK2 | |
| SCHEMBL8318732 | 0.69 | MAPK1 (0.52) | CDK4CDK2EIF2AK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606284-B1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1606284-A1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004083203-A1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | PRKCH, MAP3K20, PACSIN2 | CDK4 380/4885CDK2 106/4885EIF2AK2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.